Skip to main content

Table 1 Gender and Age Distribution of ICIs-Related Myocarditis

From: Immune checkpoint inhibitors-related myocarditis in patients with cancer: an analysis of international spontaneous reporting systems

  Pembrolizumab Nivolumab Atezolizumab Avelumab Durvalumab Cemiplimab Ipilimumab
EV FAERS EV FAERS EV FAERS EV FAERS EV FAERS EV FAERS EV FAERS
Total 177 46 296 309 26 70 2 16 18 11 2 3 104 155
Age distribution
  < 18Y 0 0 0 43 0 5 0 0 0 1 0 3 0 20
 18-64Y 37 14 55 93 11 33 0 7 3 0 0 0 19 41
 65-85Y 96 26 82 170 12 31 2 9 8 5 0 0 28 94
  > 85Y 6 6 3 3 0 0 0 0 1 1 0 0 0 0
 Unknown 38 0 156 0 3 1 0 0 6 4 2 0 57 0
Gender distribution
 Female 50 15 94 113 12 27 0 5 5 0 0 0 34 53
 Male 117 25 188 172 14 40 2 10 11 10 0 2 65 89
 Unknown 10 6 14 24 0 3 0 1 2 1 2 1 5 13
  1. Abbreviations: ICIs immune checkpoint inhibitors; EV EudraVigilance; FAERS Food and Drug Administration (FDA) Adverse Event Reporting System